Polyrizon Ltd. (PLRZ)
NASDAQ: PLRZ · Real-Time Price · USD
10.75
+1.75 (19.44%)
At close: Oct 30, 2026, 4:00 PM EDT
10.54
-0.21 (-1.95%)
After-hours: Oct 30, 2026, 7:30 PM EDT
Polyrizon Employees
As of December 31, 2025, Polyrizon had 4 total employees, including 2 full-time and 4 part-time employees. The number of employees decreased by 2 or 33.33% compared to the previous year. That makes Polyrizon the 42,503rd largest employer in the world and 6,796th in the United States.
Employees
4
Change (1Y)
-2
Growth (1Y)
-33.33%
Revenue / Employee
n/a
Profits / Employee
-$1,145,500
Market Cap
26.11M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 4 | -2 | -33.33% | 2 | 2 |
| Dec 31, 2024 | 6 | - | - | 2 | 4 |
Related Stocks
| Company Name | Employees |
|---|---|
| Karyopharm Therapeutics | 228 |
| IGC Pharma | 70 |
| BeyondSpring | 44 |
| Kyntra Bio | 34 |
| Quantum BioPharma | 17 |
| Atossa Therapeutics | 16 |
| Context Therapeutics | 15 |
| Cocrystal Pharma | 10 |
PLRZ News
- 5 days ago - Polyrizon Announces Successful Completion Enrollment of all 120 Patients in U.S. Clinical Study of NASARIX Allergy Blocker - GlobeNewsWire
- 27 days ago - Polyrizon files U.S. patent application for mucoadhesive technology - TheFly
- 27 days ago - Polyrizon Files for U.S. Patent Application to Expand IP Moat Around Intranasal Drug-Delivery Platform - GlobeNewsWire
- 5 weeks ago - Polyrizon enrolls first patient in U.S. study of NASARIX - TheFly
- 5 weeks ago - Polyrizon Enrolls First Patient in U.S. Clinical Study of NASARIX (PL-14) Allergy Blocker - GlobeNewsWire
- 6 weeks ago - Polyrizon files to sell 404,166 ordinary shares for holders - TheFly
- 1 month ago - Polyrizon Ltd. Announces Closing of $4.0 Million Registered Direct Offering and Private Placement - GlobeNewsWire
- 1 month ago - Polyrizon announces $4.0M registered direct offering - TheFly